Electra Therapeutics, Inc. (NASDAQ:ETRA – Get Free Report) Director Orbimed Advisors Llc bought 71,367 shares of the firm’s stock in a transaction on Wednesday, November 4th. The shares were acquired at an average cost of $7.53 per share, with a total value of $537,393.51. Following the purchase, the director directly owned 5,189,871 shares of the company’s stock, valued at approximately $39,079,728.63. This represents a 1.39% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Orbimed Advisors Llc also recently made the following trade(s):
- On Thursday, November 5th, Orbimed Advisors Llc bought 156,091 shares of Electra Therapeutics stock. The shares were acquired at an average price of $7.31 per share, with a total value of $1,141,025.21.
- On Tuesday, November 3rd, Orbimed Advisors Llc bought 245,113 shares of Electra Therapeutics stock. The shares were acquired at an average price of $7.86 per share, with a total value of $1,926,588.18.
- On Monday, September 21st, Orbimed Advisors Llc purchased 1,333,333 shares of Electra Therapeutics stock. The stock was bought at an average cost of $15.00 per share, for a total transaction of $19,999,995.00.
Electra Therapeutics Stock Performance
Electra Therapeutics stock opened at $7.80 on Friday. Electra Therapeutics, Inc. has a twelve month low of $6.86 and a twelve month high of $15.50.
Analyst Ratings Changes
Several equities research analysts have commented on ETRA shares. JPMorgan Chase & Co. started coverage on Electra Therapeutics in a report on Thursday, October 22nd. They issued an “overweight” rating and a $36.00 target price on the stock. Wall Street Zen upgraded Electra Therapeutics to a “hold” rating in a report on Saturday, September 26th. HC Wainwright initiated coverage on Electra Therapeutics in a research report on Monday, October 26th. They issued a “buy” rating and a $30.00 price target for the company. Evercore assumed coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They issued an “outperform” rating and a $36.00 price target on the stock. Finally, Cantor Fitzgerald began coverage on shares of Electra Therapeutics in a research report on Tuesday, October 13th. They set an “overweight” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Electra Therapeutics has a consensus rating of “Buy” and a consensus target price of $33.50.
View Our Latest Stock Report on ETRA
Electra Therapeutics News Summary
Here are the key news stories impacting Electra Therapeutics this week:
- Positive Sentiment: OrbiMed Advisors acquired 472,571 shares from November 3–5 for approximately $3.6 million, increasing its reported stake. The repeated purchases are the clearest recent potential positive catalyst for ETRA. Article on insider purchases
- Neutral Sentiment: The company is scheduled to present at the Jefferies Global Healthcare Conference on November 18. The appearance could raise its profile, but the announcement did not include new clinical or business updates. Conference announcement
About Electra Therapeutics
Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function.
Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.
Featured Articles
- Five stocks we like better than Electra Therapeutics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Electra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
